Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

Lai, Ching‐Lung; Gane, Edward; Liaw, Yun‐Fan; Hsu, Chao‐Wei; Thongsawat, Satawat; Wang, Yuming; Chen, Yagang; Jenny Heathcote, E.; Rasenack, J.; Bzowej, Natalie; V. Naoumov, Nikolai; M. Di Bisceglie, Adrian; Zeuzem, Stefan; Myoung Moon, Young; Goodman, Zachary; Chao, George; Fielman Constance, Barbara; Brown, Nathaniel

doi:10.1056/nejmoa066422

Public

Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

Published in New England Journal of Medicine • Dec 19, 2007

Authors:

Ching‐Lung Lai

Edward Gane

Yun‐Fan Liaw

Abstract

BACKGROUND: Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B. METHODS: In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudi...

Subject

Medicine

Lamivudine

Telbivudine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!